Skip to cookie consent Skip to main content

About Mass General Brigham Ventures

We are an early-stage venture capital firm founded in 2008 to advance new life science technologies emerging from Mass General Brigham, one of the United States’ most renowned health systems for medical research. Our mission is to bring more bench-to bedside innovations to market to dramatically expand our positive impact on the quality of healthcare worldwide. 

financial graph on abstract background

Our investment strategy

We invest in next-generation life science companies based on intellectual property created within our own research community.  We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle.

In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies.


More than $450 million

in capital from internal and external sources

Competitive advantage of Mass General Brigham

The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors.

Academic medical centers 

We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School. 

Our founding members

Specialty hospitals

$2.4 billion non-dilutive capital

Annual research budget

microscope drawing

7,100 Harvard Medical School faculty

Largest affiliate of Harvard Medical School

group of providers drawing

3,900 principal investigators

Leading innovative science

Industry expertise

Investing to transform patient outcomes 

We support inventors, entrepreneurs, and scientists across a range of sectors including: